Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss – Reproduction and Fertility
Reproduction and Fertility shared a post on LinkedIn:
“Day 4 of RaFJC – Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss (RPL)
Recurrent pregnancy loss (RPL) (two or more consecutive miscarriages) affects 1–2% of couples worldwide. Up to 50% of cases remain unexplained, with immune maladaptation at the maternal–fetal interface increasingly recognised as a key driver.
Current therapies rely on systemic immunosuppression (corticosteroids, IVIG, TNF inhibitors), which:
- Show inconsistent efficacy
- Carry significant risks
- Are costly and not always accessible
This highlights the urgent need for localised, safer, and cost‑effective therapies.
Mohsen Dashti, Vinnie A., and Mehdi Yousefi propose a placenta‑targeted nanoparticle (NP) system for localized immune cloaking.
Core design:
- PLGA biodegradable matrix
- Lipid‑PEG stealth layer to prolong circulation
- SPIONs for imaging and tracking
- Placental‑homing peptides for site‑specific delivery
Evidence so far:
- Rodent and primate models show placenta‑specific NP delivery is feasible
- NPs can induce anti‑inflammatory cytokines, suppress cytotoxic NK/T cells, and remodel spiral arteries
- Ex vivo human placenta models confirm uptake with minimal fetal exposure
Estimated cost: $0.56–$5.58 per dose, far cheaper than IVIG or biologics. Production is scalable.
In conclusion, placenta‑targeted nanoparticles represent a promising therapy for unexplained RPL, offering localized immune tolerance while avoiding systemic risks.
Read the full article.
Join the discussion in the comments:
- What challenges must be overcome for clinical translation?
- How might localised immune cloaking reshape patient care?
- Which biomarkers should guide future trials?
Explore the Special Collection: Immune Regulation and Inflammatory Mechanisms in Reproductive Health and Disease.”

Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 29, 2026, 01:03Seeking a Second Opinion Is Not Being Difficult, It Is a Valid Part of Informed Care – PCOS Awareness Association
-
Jul 29, 2026, 00:57Szabo Gabor: IOTA Day 2026 Advancing Ultrasound in Gynaecological Oncology
-
Jul 29, 2026, 00:55Islam Badr: A Simple Approach to Fetal Heart Screening
-
Jul 29, 2026, 00:50Hardeep Singh: Understanding the Global IVF Travel Landscape
-
Jul 29, 2026, 00:48Asma Khatun: Shaping the Future of Women’s Healthcare at GFWH 2026
-
Jul 29, 2026, 00:43Shaping the Future of Reproductive Medicine at ASRM Innovate – ASRM
-
Jul 29, 2026, 00:37George Condous: Gratitude Makes Every Achievement Greater!
-
Jul 29, 2026, 00:35As AMH Falls, Progesterone May Rise Earlier in Ovarian Stimulation! – Fertility Plus
-
Jul 29, 2026, 00:33An Easy Method for Systematic Fetal Cardiac Screening – ISUOG
